Premium
COVID‐19: Clinical status of vaccine development to date
Author(s) -
Kumar Sunny,
Basu Malini,
Ghosh Pratyasha,
Ansari Aafreen,
Ghosh Mrinal K.
Publication year - 2023
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.15552
Subject(s) - medicine , clinical trial , vaccination , covid-19 , intensive care medicine , repurposing , clinical research , disease , immunology , infectious disease (medical specialty) , ecology , biology
Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)‐induced COVID‐19 is a complicated disease. Clinicians are continuously facing difficulties to treat infected patients using the principle of repurposing of drugs as no specific drugs are available to treat COVID‐19. To minimize the severity and mortality, global vaccination is the only hope as a potential preventive measure. After a year‐long global research and clinical struggle, 165 vaccine candidates have been developed and some are currently still in the pipeline. A total of 28 candidate vaccines have been approved for use and the remainder are in different phases of clinical trials. In this comprehensive report, the authors aim to demonstrate, classify and provide up‐to‐date clinical trial status of all the vaccines discovered to date and specifically focus on the approved candidates. Finally, the authors specifically focused on the vaccination of different types of medically distinct populations.